Oral presentation at ASGCT showcases breakthrough technology enabling precise in vivo genome editing in the CNS using a ...
ROCKVILLE, Md. May 8, 2026 /PRNewswire=YONHAP/ -- USA -- AAVnerGene Inc. today announced the launch of AAVone®2.1, the ...
AAVnerGene Inc. today announced the launch of AAVone®2.1, the next-generation evolution of its proprietary AAVone® ...
The AAV vector manufacturing market is mainly fueled by the expanding landscape of gene therapy research and development, as AAV vectors are extensively utilized for therapeutic gene delivery because ...
With this information in hand, researchers who, for instance, are developing a gene therapy to treat a muscle condition, could use the atlas to identify AAV vectors that preferentially target the ...
High-throughput virology, design of experiments, and small-molecule production enhancers optimize yield and increase ...
The first vector-delivered gene therapies to receive FDA approval for clinical use were Luxturna,1 Spark Therapeutics’ vision loss cure, and Zolgensma,2 Novartis’ spinal muscular atrophy treatment.
DUBLIN--(BUSINESS WIRE)--The "Adeno Associated Virus Vector Manufacturing Market Size, Share & Trends Analysis Report By Scale Of Operations (Clinical, Commercial), By Method, By Application, By ...
AAVnerGene Inc. today announced the launch of AAVone2.1, the next-generation evolution of its proprietary AAVone single-plasmid AAV production ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results